Yaman, E. Et Al. 2008. Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171). ANNALS OF ONCOLOGY , vol.19, no.2 , 397-398.

Yaman, E., Benekli, M., Coskun, U., Ozturk, B., Kaya, A. O., Yildiz, R., ... Buyukberber, S.(2008). Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171). ANNALS OF ONCOLOGY , vol.19, no.2, 397-398.

Yaman, E. Et Al. "Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171)," ANNALS OF ONCOLOGY , vol.19, no.2, 397-398, 2008

Yaman, E. Et Al. "Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171)." ANNALS OF ONCOLOGY , vol.19, no.2, pp.397-398, 2008

Yaman, E. Et Al. (2008) . "Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171)." ANNALS OF ONCOLOGY , vol.19, no.2, pp.397-398.

@article{article, author={E. Yaman Et Al. }, title={Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171)}, journal={ANNALS OF ONCOLOGY}, year=2008, pages={397-398} }